@article{article, title = {{A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS).}}, publisher = {{American Society of Clinical Oncology (ASCO)}}, url = {{}}, year = {{2013}}, month = {{5}}, author = {{Talbot DC and Blackhall FH and Kowalski D and Ramlau R and Bepler G and Grossi F and Lerchenmuller CA and Pinder MC and Mezger J and Danson S and Callies S et al}}, doi = {{10.1200/jco.2013.31.15_suppl.8051}}, volume = {{31}}, journal = {{Journal of Clinical Oncology}}, issue = {{15_suppl}}, pages = {{8051-8051}}, note = {{Accessed on 2025/07/30}}}